Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915861 | 1.00 | MEN1 (0.44) | MEN1KMT2AALDH1A1GFERGAA | |
| SCHEMBL17074881 | 0.89 | MEN1 (0.44) | MEN1KMT2AALDH1A1GAANPSR1 | |
| SCHEMBL6524996 | 0.85 | CHEK1 (0.41) | MEN1KMT2AALDH1A1GFERGAA | |
| SCHEMBL29886595 | 0.85 | CHEK1 (0.41) | MEN1KMT2AALDH1A1GFERGAA | |
| SCHEMBL11482347 | 0.83 | KMT2A (0.45) | MEN1KMT2AALDH1A1GAANPSR1 | |
| SCHEMBL17583721 | 0.83 | ESR1 (0.39) | MEN1KMT2AALDH1A1GAANPSR1 | |
| SCHEMBL31717971 | 0.81 | MEN1 (0.41) | MEN1KMT2AALDH1A1GAANPSR1 | |
| SCHEMBL28703009 | 0.80 | ESR1 (0.35) | MEN1KMT2AALDH1A1GAANPSR1 | |
| Hydrochloric Acid SCHEMBL7503502 | 0.79 | MEN1 (0.44) | MEN1KMT2AALDH1A1GAANPSR1 | |
| SCHEMBL32677307 | 0.78 | MEN1 (0.47) | MEN1KMT2AALDH1A1GFERGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180894-A1 | METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR | BETTERLIFE PHARMA INC (CA) | 2024-06-06 | — | — | US | disclosed |
| US-11260027-B2 | Donor organ pre-treatment formulation | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-03-01 | — | — | US | disclosed |
| US-11214805-B2 | Targeted nanocarriers for the administration of immunosuppressive agents | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3094314-B1 | TARGETED NANOCARRIERS FOR THE ADMINISTRATION OF IMMUNOSUPPRESSIVE AGENTS | MUSC FOUND FOR RES DEV (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-108409630-B | Preparation method of 3-hydroxy-2-indolone derivative in aqueous phase | 宁波大学 | 2021-01-15 | — | — | CN | disclosed |
| CN-107686460-B | Preparation method of 3-substituted-3-hydroxy-2-indolone compound | 宁波大学 | 2020-06-12 | — | — | CN | disclosed |
| US-20200056183-A1 | TARGETED NANOCARRIERS FOR THE ADMINISTRATION OF IMMUNOSUPPRESSIVE AGENTS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2020-02-20 | — | — | US | disclosed |
| EP-2278966-B1 | TREATMENT WITH OPIOID ANTAGONISTS AND MTOR INHIBITORS | UNIV CHICAGO (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10428331-B2 | Targeted nanocarriers for the administration of immunosuppressive agents | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2019-10-01 | — | — | US | disclosed |
| US-10383869-B2 | Treatment with opioid antagonists and mTOR inhibitors | THE UNIVERSITY OF CHICAGO (US) | 2019-08-20 | — | — | US | disclosed |
| US-20110021551-A1 | TREATMENT WITH OPIOID ANTAGONISTS AND mTOR INHIBITORS | THE UNIVERSITY OF CHICAGO | 2011-01-27 | — | — | US | disclosed |
| US-7846962-B2 | 3-3-di-substituted-oxindoles as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100256388-A1 | 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100249201-A1 | 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737172-B2 | 3-3-di-substituted-oxindoles as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090299058-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009117669-A2 | TREATMENT WITH OPIOID ANTAGONISTS AND MTOR INHIBITORS | THE UNIVERSITY OF CHICAGO (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20070099976-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1718611-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | The President and Fellows of Harvard College (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080335-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256388-A1 | 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation | EIF2AK2, EIF5B, EIF4EBP1 | MEN1 4058/4885KMT2A 3213/4885ALDH1A1 3721/4885 |
| US-20090299058-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | EIF2AK2, EIF5B, EIF4EBP1 | MEN1 4058/4885KMT2A 3213/4885ALDH1A1 3721/4885 |
| US-20070099976-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | EIF2AK2, EIF5B, EIF4EBP1 | MEN1 4058/4885KMT2A 3213/4885ALDH1A1 3721/4885 |
| US-10383869-B2 | Treatment with opioid antagonists and mTOR inhibitors | OPRL1, OPRK1, OPRM1 | MEN1 4535/4885KMT2A 1568/4885ALDH1A1 3995/4885 |
| US-10428331-B2 | Targeted nanocarriers for the administration of immunosuppressive agents | CD59, CD47, CD58 | MEN1 4210/4885KMT2A 4616/4885ALDH1A1 2129/4885 |
| US-20110021551-A1 | TREATMENT WITH OPIOID ANTAGONISTS AND mTOR INHIBITORS | OPRL1, OPRK1, OPRM1 | MEN1 4535/4885KMT2A 1568/4885ALDH1A1 3995/4885 |
| US-20100249201-A1 | 3-3-Di-Substituted-Oxindoles As Inhibitors of Translation Initiation | EIF2AK2, EIF5B, EIF4EBP1 | MEN1 4058/4885KMT2A 3213/4885ALDH1A1 3721/4885 |
| US-20200056183-A1 | TARGETED NANOCARRIERS FOR THE ADMINISTRATION OF IMMUNOSUPPRESSIVE AGENTS | CD59, CD47, CD58 | MEN1 4210/4885KMT2A 4616/4885ALDH1A1 2129/4885 |
| US-20240180894-A1 | METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR | MTOR, RICTOR, RPTOR | MEN1 1710/4885KMT2A 190/4885ALDH1A1 4604/4885 |
| US-11214805-B2 | Targeted nanocarriers for the administration of immunosuppressive agents | CD59, CD47, CD58 | MEN1 4210/4885KMT2A 4616/4885ALDH1A1 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.